Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Dr Mariana Chavez MacGregor reports on advances from ASCO 2025, emphasizing treatment de-escalation and emerging tools like ctDNA for personalized care.

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

An analysis of oral presenters at ASCO Annual Meeting revealed considerable disparities based on career stage, gender, subspecialty and geographic region.Mid- to late-career medical oncologists from ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.